Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients.

Apha-1-adrenergic receptor antagonists (α

Informations de copyright

Copyright © 2022 Li, Jun, Tyler, Schadt, Kao, Wang, Konig, Bettegowda, Vogelstein, Papadopoulos, Parsons, Chen, Schadt, Li and Oh.

Déclaration de conflit d'intérêts

SL, TJ, JT, ES, Y-HK, ZW, RC, EES, LL, and WKO were all employees of Sema4 at the time this research was conducted. Sema4 is a publicly traded, for-profit company in which the Icahn School of Medicine at Mount Sinai (ISMMS) holds equity. RC, EES, LL, and WKO receive compensation from Sema4 that includes equity in the company. In addition to their roles with Sema4, RC, EES, and WKO remain affiliated with ISSMS as part-time employees and faculty members. WKO also has consulted for AAA, Astellas, AstraZeneca, Bayer, Conjupro, Foundry, Janssen, Merck, Sanofi and TeneoBio. The JHU filed a patent application on the use of various drugs to prevent cytokine release syndromes, on which NP is listed as an inventor. JHU will not assert patent rights from this filing for treatment related to COVID-19. NP is a founder of, consultant to and holds equity in Thrive an Exact company. NP is a founder of and holds equity in Personal Genome Diagnostics. NP is an advisor to and holds equity in Cage Pharma, ManaTbio, and NeoPhore. CB is a consultant to Depuy-Synthes and Bionaut Labs. CB, MFK, and NP are also inventors on technologies unrelated or indirectly related to the work described in this article. MFK is a consultant to argenx. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict-of-interest policies. JV is supported by grants from Microsoft Research and Fast Grants. Microsoft Research and Fast Grants were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.